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Abstract: Direct to consumer advertising (DTCA) is a polarized topic, with healthcare 
professionals (HCPs), patients and policy makers involved in the debate. Opponents of 
DTC marketing believe that this practice increases the use of more expensive drugs that 
may not show a benefit over older, less expensive drugs. They argue that this practice 
leads to an overall increase in drug costs for the United States, by both influencing 
patients to ask for the advertised product, as well as indirect! y influencing physician to 
prescribe it. Opponents also feel that advertisements are skewed to inflate the benefits of 
the drugs, while mitigating the potential safety concerns of the products. Proponents of 
DTC marketing believe that mobilization of patients through increased disease awareness 
is a by-product of this practice, leading to better diagnosis and treatment of many 
patients. Surveys have shown that DTCA is believed to increase adherence to prescribed 
medications and plays a role in reducing the stigma associated with certain conditions. 
Interestingly, both patient and physician surveys addressing these issues have shown 
mixed results, leading to further debate about the impact of this practice. However, 
certain changes to the current way DTCA is being carried out could improve the 
perceived benefit that this and the pharmaceutical industry as a whole, affords the 
patients and HCPs of the United States. 
Introduction: 
The path to direct-to-consumer advertising (DTCA) has been a long and arduous 
one (Donohue, 2006; Wilkes, Bell, & Kravitz, 2000). Prior to 1938, lax drug approval 
standards meant that many drugs were available without a prescription and were 
marketed mainly to patients. This led to inherent concerns, as there were no regulations 
to control overstatements of efficacy and safety. In response to a catastrophe involving a 
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drug named elixir sulfanilamide, Congress stepped in and passed the 1938 Food, Drug, 
and Cosmetic Act (FDCA) which legally gave. the Food and Drug Administration (FDA) 
the power to approve drugs based on their safety profiles. By the 1960s, large! y due to 
this regulation, 90% of the pharmaceutical companies' spending on marketing was geared 
towards physicians with the hope that their prescribing habits would favor the marketed 
drug; the rest of the efforts were directed towards other healthcare professionals (HCPs) 
such as nurses and pharmacists. Any marketing efforts were regulated through the 
Federal Trade Commission (FTC), not the FDA, limiting their ability to regulate claims 
being made by the pharmaceutical companies. 
In the late 1950s to early 1960s, unethical pharmaceutical marketing practices 
were scrutinized, as companies over-marketed the benefits of products while minimizing 
associated risks. Congress responded in 1962 by passing legislation giving the FDA 
power to approve a product based on the products' safety and efficacy profiles. This 
amendment, the Kefauver-Harris Amendments to the FDCA, also allowed the FDA 
jurisdiction over the advertising of prescription drugs, thereby taking this power from the 
FTC. By 1969, the FDA's final advertising regulations stated that all advertisements 
must accurately present a true depiction of the actual safety, tolerability, and efficacy of 
the drug. This was termed "fair balance," indicating that though a pharmaceutical 
company could talk about a drug's demonstrated efficacy, it must do so in the context of 
the potential associated risks, thereby presenting a true risk benefit profile to the patient. 
These guidelines shaped future pharmaceutical marketing practices. 
In the 1980s, DTCA started to become more popular again. Though there was 
negative feedback initially, especially from FDA Commissioner Arthur Hill Hayes, the 
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FDA sponsored a study assessing consumer perceptions of, and their behaviors related to, 
prescription drug advertising. This study found that consumers wanted more drug 
information. In 1985, the FDA put out regulations stating that advertisements to 
consumers must meet the same requirements as those geared towards physicians. 
However, due to the difficulties in presenting all the safety and efficacy information 
included in the drug analysis, most pharmaceutical companies avoided DTC marketing of 
prescription drugs. 
As patients became more interested in learning about products and diseases, 
however, there was a shift towards an increased use of DTC marketing. In the 1990s, 
DTC marketing increased dramatically, and pharmaceutical companies found a new 
partner for their DTC initiatives with a newly conservative Congress. In 1997, the FDA 
released the Draft Guidance for Industry: Consumer-Directed Broadcast Advertisements, 
which shortened the brief summary requirements for broadcast ads. (Food and Drug 
Administration [FDA], 1997). The final version was released in 1999. This led the way 
to a growth of DTC marketing that some believe was unforeseen by many FDA officials 
(Donohue, 2006). 
Today, while much of the marketing is still aimed at HCPs, use of patient-
oriented marketing has skyrocketed and now accounts for about 40% of pharmaceutical 
promotional spending. To demonstrate the growth curve, Intercontinental Marketing 
Services (IMS) records report that in 1993, $166 million was spent on DTCA; in 2005 
that figure rose to $4.2 billion. For certain products, DTCA is now the leading expense 
in some pharmaceutical companies' promotional spending budget. The average 
American television viewer sees as many as 16 hours of prescription drug advertisements 
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per year, far exceeding the average 15 minutes a patient will spend with his/her PCP 
(Frosch, Krueger, Hornik, Cronholm, & Barg, 2007; Brownfield, Bernhardt, Phan, 
Willians & Parker, 2004). 
Throughout its history, DTC marketing has been a controversial topic. 
Multidisciplinary groups, including policy makers, HCPs, consumer groups, industry 
groups and others, have tried to shed light on whether DTC marketing is, in fact, 
beneficial or detrimental to the US public healthcare system (Donohue, 2006; Wilkes et 
al., 2000). This paper will report evidence for both the perceived positive and negative 
effects of DTC marketing and suggest guidance to better utilize DTC marketing to help 
achieve public health goals. 
Reviewing the Evidence: The Opposition to DTC Marketing. 
The reasoning behind opposition to DTCA is well known. There are dangers, 
critics maintain, to marketing a pharmaceutical product the same way one would market a 
bar of soap or another consumer product. Challengers to DTCA's benefit in public health 
and education state that this form of marketing encourages the use of expensive newer 
drugs that do not show any additional health benefits compared to the older drugs that 
may be generic and thus, cheaper (Avorn, 2003; Hollon, 2005; Hansen, Shaheen, & 
Schommer, 2005). In fact, some feel that the increase in usage of these expensive new 
products may be a major force in increasing the United States' pharmaceutical drug 
spending (Findlay, 2002; Bachlor & Laouri, 2003). 
Opponents to DTC marketing maintain that it is skewed to show the benefits of 
products without providing a balanced presentation of potential risks, especially long-
term ones, of products (Gahart, Duhamel, Dievler, & Price, 2003; Kaphingst & Delong, 
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2004; Waxman, 2004). Additionally, DTC marketing is believed to negatively influence 
HCP and patient dynamics, forcing physicians to spend more time with patients to correct 
inaccurate perceptions they may have due to the marketing efforts (Bellard, 2004; 
Robinson et al., 2004). A large majority of stakeholders, including physicians and 
patients, believe that the drug industry is too aggressive in promoting the unapproved 
uses of their products and present too little usable data about their products, presumably 
because they hear about these practices through the lay press (Price Waterhouse Coopers 
[PWC], 2007). A majority of surveyed participants believed that pharmaceutical 
companies manipulate data and present the best data to sell their drugs while minimizing 
the benefits of generic formulations. The upcoming section will review the evidence for 
these claims. 
Newer drugs, but no new benefit? 
One of the main reasons opponents of DTCA are so defiantly against this type of 
marketing is that many of the recently approved drugs are reproductions of older drugs 
with little advantage in safety or efficacy, but at a higher cost for patients and the 
healthcare system (Avom, 2003; Hollon, 2005; Hansen et al., 2005). In fact, some high 
profile studies seem to support this opinion. Two such studies are described. 
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) compared the use of diuretics, an important, if older, class of 
antihypertensive drug, with some of the newer classes of antihypertensive medications, 
such as angiotensin converting enzyme inhibitors (ACE-Is) and calcium channel blockers 
(CCBs) (Davis et al., 2006; Ahmed, 2004; Siragy, 2003; ALLHAT Officers and 
Coordinators for the ALLHAT Collaborative Research Group, [ALLHAT CRG]2002). 
6 
Master's Paper Final 
4/2/2007 
Serena Tsai 
In this study, patients receiving a diuretic, plus an optimal treatment regimen without 
ACE-I and CCBs, experienced fewer cardiovascular events than patients taking ACE-Is 
or CCBs plus an optimized regimen. Additionally, patients on diuretic regimen had a 
lower incidence of heart failure and strokes compared to those on an ACE-I regimen. 
This 40,000 patient trial suggests that giving diuretics as the first line therapy 
instead of ACE-Is and CCBs, should be standard practice for indicated patients. 
Additional analysis assessing the differential costs of using the more expensive products 
also added to the debate (Anderson, 2003). According to some pharmacoeconomic 
analyses, diuretics cost between $0.06 and $0.10 a day, while an ACE-I could cost up to 
$1.46 a day. Switching from this newer class of drug to a diuretic could result in a 
savings of $250.00 to $650.00 per patient, per year (Hansson, 1997). A retrospective cost 
analysis of US data collected between 1985 and 1992 showed that the yearly cost of 
diuretics was about $133.00 compared to approximately $444.00 per year for ACE-Is. 
Though recently at least three ACE-Is have gone generic, studies such as the Heart 
Outcomes Prevention Evaluation (HOPE) trial that showed protective cardiovascular 
benefits for a specific, branded ACE-I, ramipril, continue to convince many physicians to 
use the more expensive branded ACE-Is instead of generic products (Heniels et al., 
2003). 
However, when other healthcare costs, such as supplemental care, laboratory tests 
and hospital and clinic visits were accounted for, the actual difference between the 
treatments was slightly less, wlth the total cost with diuretics coming out to be about 
$1043.00 versus $1243.00 for the ACE-I treatment regimen (Hilleman et al., 2004). 
Also, there were some limitations of the trial design. Many suggest that this trial did not 
7 
Master's Paper Final 
4/2/2007 
Serena Tsai 
incorporate optimal treatment of the patients, as, ideally, many patients would have 
gotten a combination of diuretics and ACE-Is or CCBs to achieve better blood pressure 
control and to further reduce their potential for a cardiovascular event (Fagard, 2003; 
Unger, 2004). 
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial was 
conducted by the National Institute of Mental Health (NIMH). The trial was done to 
compare tbe safety and efficacy between the different atypical anti psychotics, the newer 
agents for treatment of schizophrenia, and between those agents and the typical 
anti psychotics, or the older products (Nasrallah, 2007; Stroup et al., 2006; Envoy et al., 
2006; Lieberman et al., 2005). The newer anti psychotics are prescribed for a majority of 
cases even though they are significantly more expensive than the typical anti psychotics 
because there is a widespread perception of slight increase in efficacy and tolerability 
over the older class of anti psychotics (De Oliveira & Juruena, 2006). 
CATIE showed that there was no statistically significant difference in overall 
effectiveness between the atypical anti psychotics and the first generation products. 
Additionally, economic analyses showed that patients who took the older products have 
total monthly health costs up to 30% lower than those who took the more expensive 
second generation products (Rosenheck et al., 2006). The NIMH concluded that the 
older anti psychotics can still play a major role in treating schizophrenia. 
As in the case of ALLHAT, there is compelling data to suggest that the older 
products should be used more often. However, as in the case of ALLHAT, there were 
issues with the design of this study. Due to the well known side effects of the older 
anti psychotics, termed extrapyramidal side effects or EPS, a collection of movement 
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disorders, patients who were known to be susceptible to EPS were excluded from the arm 
of patients who were supposed to get the older drug, perphenazine. Still, people in the 
perphenazine group were more likely to suffer from EPS and drop out of the trial due to 
these symptoms (Glick, 2006; Casey, 2006). Therefore, the role of older generation 
drugs in schizophrenia is still under question. 
These are just two studies suggesting that the usage of newer and more marketed 
brands may not necessarily provide great benefits to all patients. In these two cases, 
generic products provide at least comparable efficacy to the newer products used to treat 
the same disease. A large number of recently surveyed consumers seem to believe that 
pharmaceutical companies choose to develop "me too" and "lifestyle" drugs instead of 
drugs that fulfill an important role in disease treatment (PWC, 2007). Critics of DTC 
marketing argue that the higher profile of marketed products drives patients to ask for 
those specific products leading to more frequent, and sometimes inappropriate, 
prescribing of the more expensive drugs, resulting in immense increases in the nation's 
pharmaceutical drug spending (Avorn, 2003; Batchlor & Laouri, 2003; Vogel, 
Ramachandran, & Zachry, 2003). 
Is there a relationship between DTC marketing and pharmaceutical drug spending? 
Costs for all aspects of healthcare in the United States have been rising and are 
expected to continue to do so (Cutler, Rosen, & Vijan, 2006; Borger et a!., 2006; Smith, 
Cowan, Heffler, & Catlin, 2006). The question is, however, whether DTC marketing 
contributes to the rise in pharmaceutical drug spending. The Kaiser Foundation did some 
research to further elucidate this issue concluding, "on average, a 10% increase in DTC 
advertising of drugs within a therapeutic drug class resulted in a 1% increase in sales of 
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the drugs in that class". Further analyses assessing the 25 drug classes with the highest 
retail sales in 2000 suggested that every dollar the pharmaceutical industry spent on 
DTCA yielded an additional $4.20 in drug sales, leading to a 12% increase in prescription 
drug sales or an additional $2.6 billion in 2000 (Henry J Kaiser Foundation [HJKF], 
2003). 
This is supported by the United States General Accounting Office's Report to 
Congressional Requesters, released in October 2002. The report notes that "prescription 
drug spending increased at an annual rate of about 18 percent from 1997 through 2001 
and is the fastest growing component of health care spending in the United States." They 
note that those products directly promoted to patients tend to be the highest selling 
products, with the number of prescriptions for the most frequently advertised drugs rising 
up to 25% compared with 4% of drugs that were not heavily advertised (United States 
General Accounting Office [GAO], 2002). 
Interestingly, the increase in drug spending had little to do with the rise of 
individual drug costs. From 1999 to 2000, the wholesale cost for highly marketed 
products only rose 6% compared with 9% for those that were not heavily marketed. 
Therefore, the GAO (2002) concluded that a major rise in prescription drug spending is 
actually due to the increasing number of patients being treated with a marketed 
prescription product. The question is whether the drugs are being prescribed for 
medically necessary conditions, or whether patients are simply getting medications just 
because they ask their physician for them. 
Aiken, Swasy, and Braman (2004) tried to answer this question, noting that 
although 42% of patients expected a prescription at their most recent visit with their 
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doctor, most of them, 63%, expected this because they were asking for a refill of their 
current prescription; the commercials simply serve to remind them to ask their physician 
for a refill. Seventeen percent of patients believed that they truly had the disease and 
knew the drug would work for them, likely because they had previously suffered from the 
same condition in the past. Aiken and company showed that only 6% of patients said that 
they wanted a prescription due only to a television broadcast advertisement and 5% 
claimed that a print advertisement led them to expect the medication. 
The healthcare professional-patient dynamic: a negative influence resulting in tension 
and unnecessary prescriptions? 
The HCP is seen as the mediator between the pharmaceutical industry and the 
consumer, or patient (Donohue, 2006; Welch-Cline& Young, 2004). Therefore, 
opponents of DTCA claim that DTCA strategies are inevitably harming the relationship 
between HCPs and their patients (Robinson eta!., 2004). Critics assert that patients 
asking for specific, advertised products make the physicians uncomfortable, bring tension 
into the relationship, and contribute to excess drug use simply because of the request 
(Allison-Ottey, Ruffin, & Allison, 2002). In addition, critics claim that physicians are 
already pressed for time with patients and that DTC marketing forces physicians to spend 
valuable time explaining and correcting misconceptions that are a result of DTCA, 
thereby reducing time efficiency (Robinson eta!., 2004; Aiken, 2003; Murray, Lo, 
Pollack, Donelan, & Lee, 2003). 
There seems to be evidence to support these statements. Wilkes, Bell and Kravitz 
(2000) show in their analysis of the trends of DTC marketing that even given the push 
from managed care to increase the use of generic drugs, many of the prescriptions being 
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written still tended to be for branded products. According to Allison-Ottey' s (2002) 
study, a survey of almost 900 general practitioners (GPs) and specialists, showed that of 
those physicians that were asked by their patient for a specific treatment, 38% of them 
felt additional pressure to justify which treatment they prescribe. Another study showed 
that 18% of the GPs surveyed felt that patients bringing up an advertisement led to 
problems, including time needed to correct misconceptions. More than 40% of patients 
in this study reported that they expected to get an advertised product with 69% reporting 
that they did indeed receive that product. Approximately half of the GPs surveyed did 
not feel any pressure to prescribe, and 50% felt some pressure; 7% of GPs reported 
feeling very pressured to prescribe a specific product. (Aiken 2003; Aiken, 2005) 
Additionally, these studies showed that more than 60% of surveyed physicians 
felt increased tension because of DTCA, with about 80% attributing the tension to 
patients' questioning and second guessing their diagnosis (Aiken 2003). Though the 
numbers were lower, Slaughter's study for Prevention magazine (2003), supported this 
result by showing that 36% of physicians surveyed also believed that DTC marketing 
introduced tension into their relationships with patients, with 32% of them feeling that 
DTC made patients question their judgment and ability to treat them. 
As a result of this increased tension, many physicians just prescribe the product 
that their patients ask for. In one study, 40% of the physicians surveyed prescribed the 
requested drug and but less than half of them were positive that it was the best drug for 
the patient. Almost 50% felt that other drugs would have been as effective but they 
wanted to accommodate the patients' requests. Fortunately, very few physicians truly felt 
that another drug or treatment option would have been significantly better for their 
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patients, suggesting that physicians will not prescribe treatments if they feel their patients 
would be in danger (Weissman eta!., 2004). 
Other surveys showed that up to three quarters of surveyed GPs and specialists 
believed that DTC marketing pressured them into prescribing a drug that they would not 
have normally prescribed (Lipsky & Taylor, 1997; Aiken, 2003; Murray, eta!., 2003). It 
is important to note that in many cases patients requested an additional test, change in 
medication, or specialist referral-the request was not specific to just wanting the 
medication shown in the DTC advertisement (Murray et al.). 
Although all studies show that some physicians feel pressured to prescribe a 
specific product, some studies show that the actual effect is minimal. One study, for 
instance, showed that 89% of physicians said that their prescribing habits have not 
changed as a result of the ads, with 61% of physicians saying they don't feel additional 
pressure to justify their choices (Allison-Otley et al., 2002). Additionally, there may be 
differences in perception of pressure depending on whether the physician is a general 
practitioner or a specialist, with specialists feeling less pressure to prescribe according to 
patients' requests (Aiken 2003; Aiken, 2005; Petroshius, Titus, & Hatch, 1995). An 
Aiken (2003) study showed that over 90% of the surveyed physicians felt that the patient 
did not try to influence the course of treatment in a way that would have been harmful to 
him/her. Another multi-specialty physician survey showed that 36% of surveyed 
physicians were seriously concerned and 40% were moderately concerned about 
physicians being influenced by pharmaceutical companies to prescribe a certain product 
through direct contact with sales representatives, as well as DTCA; approximately the 
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same number of physicians was also worried about the potential habit of over-treating 
patients (Weber, 2005). 
The Wilkes (2000) study demonstrated that many patients would be upset if their 
request for a specific product was not fulfilled. Half of the respondents felt that they 
would be disappointed if the physician turned down their request, 25% anticipated that 
they would try to change the doctor's mind, 24% thought they might attempt to obtain the 
prescription from a different doctor and 15% thought that they might switch to a new 
doctor. 
The prescribing trends for one specific type of drug are often used to support the 
claim that physicians will prescribe other unnecessary products. As antibiotic-resistance 
continues to increase, the worry is that in the future, other strains of bacteria may become 
resistant to currently available antibiotics. In fact, according to the FDA, about 70% of 
bacteria that presently cause infections in hospitals are resistant to at least one of the 
drugs most common! y used to treat those infections. Goossens et al. (2005) conducted an 
analysis across Europe to assess resistance profiles, showing that those countries with the 
highest use of antibiotics tended to have the most resistant pathogens. Another study 
showed that of patients who had a diagnosis of common cold or upper respiratory tract 
infection, more than one third of patients received antibiotics even though the disease was 
viral, not bacterial (Gilberg, Laouri, Wade & Isonaka, 2003). 
Is fair balance really being accurately presented? 
Critics of DTC marketing claim that marketing pieces directed towards the 
consumer are biased to show the benefits of the drug, while minimizing any potential 
risks associated with taking the product. In order to better clarify whether this perception 
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is held by botb patients and HCPs, many groups have conducted surveys to assess this 
phenomenon. 
Multiple studies have shown that most physicians surveyed believe that patients 
confuse the relative risks and benefits of advertised products, with the majority of 
physicians also believing that their patients tbink that the drug is more effective than 
clinical evidence shows. Physicians in these studies also believe that, overall, DTCA 
does not provide information in a balanced manner and that DTCA encourages patients to 
seek a treatment that they may not need (Aiken 2003; Weissman eta!., 2004; Slaughter, 
2003). 
Golodner's (2003) survey, another FDA-sponsored study from 2003, assessed 
patient opinions and showed that 60% of patients believe advertisements are mainly to 
help the pharmaceutical industry sell their drugs, with almost 50% of patients saying that 
these advertisements encourage patients to ask for drugs that they do not need or can not 
take. Since 2003, patient perception of the pharmaceutical industry has fallen even 
further, as results of the Price Waterhouse Cooper's (2007) patient surveyed showed a 
burgeoning distrust of the industry as a whole, with results showing that patients felt that 
profits are the most important goal for the pharmaceutical companies. The questionnaire 
provided a glimpse into why that has happened, with the majority of surveyed 
stakeholders believing that pharmaceutical companies often manipulate or suppress 
negative clinical trial results or prevent the sales of generic products in order to profit 
from their more expensive branded products. 
There were additional investigations that assessed the ads themselves to determine 
the balance of benefits versus risks. Frosch et al.'s (2007) study showed that almost 95% 
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of product claim ads and 100% of the reminder ads they assessed used positive emotional 
appeals, often by depicting a happy character after taking the product. Sixty-nine percent 
of the ads used negative emotional appeals such as showing a character in a fearful state 
before using the product. Wilkes eta!. (2000) assessed advertisements between 1989 and 
1998 and showed that the most common appeals used were claims of effectiveness and 
symptom control. The advertisements also focus on the "innovativeness" of the product 
and try to sell the potential convenience associated with it. 
Although the FDA is supposed to be watching out for these biased depictions, 
detractors maintain that the FDA does not have the manpower to adequately monitor the 
marketing tactics of the pharmaceutical industry and in many cases, penalizes companies 
long after consumers have been subjected to false claims. In addition, current regulations 
may handicap the FDA from sending out timely warnings to pharmaceutical companies 
(Donohue, 2006; Gahart eta!., 2003). In late 2001, the United States Department of 
Health and Human Services required the FDA to wait for the approval of the Office of 
Chief Counsel before regulatory letters could be issued (GAO, 2002). 
Due to this additional step in the process, the length of time before a warning 
letter would be sent to the pharmaceutical company for a misleading advertisement 
increased significantly. These misleading advertisements may have completed their 
broadcast life cycle before the FDA issued the letters. Further evidence critics use to 
demonstrate the ineffectiveness of the FDA is the decrease in warning letters issued by 
the FDA. The number of warning letters issued by the agency for violations of federal 
advertising requirements has fallen by over 50%, from 1154 in 2000 to 535 in 2005, a 15 
year low (GAO, 2002; Waxman, 2004). 
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Reviewing the Evidence: The Proponents of DTC Marketing. 
With all this evidence against DTC marketing, what are proponents saying to 
support it? Supporters of DTC marketing believe that this type of marketing has raised 
awareness of many diseases that affect both morbidity and mortality. This increased 
awareness leads to improved health-seeking behavior by patients, empowers them, and 
allows for better and more productive dialogue between HCP and patient, which is 
believed to result in better diagnosis and treatment. In fact, DTC marketing advocates 
say it is an important approach to building better partnerships between HCPs and 
patients, by helping to educate patients so that they are more likely to have an educated 
and informed conversation with their HCP. Furthermore, DTC marketing is thought to 
de-stigmatize certain diseases, leading to more awareness and better treatment 
(Pharmaceutical Research and Manufacturers of America [PhRMA], 2005; National 
Medical Association [NMA], 2002; Calfee, 2005; Murray et al., 2004). This section will 
review the evidence for these claims, which, interestingly, come from the same studies 
and surveys that also report on the negative perceptions of DTC marketing. 
Does DTC increase disease awareness, help seeking behavior, patient understanding of 
disease and patient empowerment? 
According to December 2003 Federal Trade Commission comments to the FDA, 
"[DTCA] can empower consumers to manage their own health care by providing 
information that will help them, with the assistance of their doctors, to make better 
informed decisions about their treatment options .... Consumers receive these benefits 
from DTC advertising with little, if any, evidence that such advertising increases 
prescription drug prices" (Federal Trade Commission [FTC], 2003). This is important 
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considering that there is rampant under-diagnosis and under-treatment of many diseases, 
including asthma, cerebrovascular disease, congestive heart failure, diabetes, hip fracture, 
hyperlipidemia, and hypertension. (Shrank eta!., 2006; "Landmark Study Finds American 
Adults Often Fail to Get Recommended Care, Posing 'Serious Threats' to Health,", 2003; 
Bhatt et a!., 2006). 
Eighteen percent of patients surveyed in Aiken's (2003) study claimed that an 
advertisement caused him/her to talk to his/her doctor about a medical condition or 
illness that they had never approached their doctor with before, with 87% of patients who 
requested a prescription actually having the disease. More than half of the surveyed 
patients agreed that these advertisements gave them enough information to decide 
whether they should discuss the drug with their physician and just less than half of the 
patients believed that the advertisements helped them have better discussions with their 
doctors. One third of patients believed that the advertisements helped them make better 
decisions about their health. 
The surveyed physicians agreed; about 79% of physicians believed that DTC 
increased patient awareness of diseases earlier, 95% of physicians believed that patients 
are more aware of possible treatments, and 90% of physicians believe their patients are 
more involved in their healthcare. In fact, 78% of physicians stated that patients are more 
likely to seek treatment for potentially serious conditions, due to DTC marketing (Aiken, 
2004). Results like these are seen in other studies as well (Slaughter, 2003; Lipsky & 
Taylor, 1997). Interestingly, after further analysis, Weissman eta!. (2004) concluded that 
"approximately 41 percent of conditions initially discussed during the visit and 30% of 
new diagnoses were 'high priority' conditions according to the Agency of Healthcare 
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Research and Quality. Institute of Medicine (AHRQIIOM) criteria." These conditions 
include four of the five most costly classes of conditions in 2002: heart conditions, 
cancer, mental disorders and pulmonary conditions (Olin & Rhoades, 2005). 
In a specific study evaluating nicotine patches, results suggested that DTCA 
encouraged patients to seek treatment for smoking cessation; as 36% of patients first 
learned about the nicotine patch from the media, supporting the claim that DTCA 
influences patients to seek care (Lipsky & Taylor, 1997). Aiken et al. (2005) reported 
that almost 40% of respondents thought that DTC advertisements encourage patients to 
look for more information about potentially serious medical conditions. 
Golodner (2006) reported that 31.% of patients decided to talk to their doctor 
about a specific product, while 26% of patients sought more information. To obtain more 
information, 16% of patients talked to their pharmacist, 14% looked for information on 
the internet and 10% of patients talked to a nurse or called a toll-free information line set 
up by the pharmaceutical company. Twenty-one percent of patients said they felt more 
informed about the medicine advertised, 19% felt that it made them better able to address 
their health conditions and of those who actually did manage to speak to their doctors 
about the treatment, half reported that they wanted to find out if the medication was right 
for them while about 30% of patients said they wanted to find out the best way to treat 
their condition. Only 10% wanted or expected to get the drug that was advertised 
although 42% of them did a number consistent with what was shown in the Aiken studies 
(Aiken 2003; Aiken 2005). 
Does that translate into better treatment? 
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Although most studies do show that 40% to 80% of patients will get the drug they 
speak to their HCP about, other treatment options are also discussed (Datti & Carter, 
2006; Slaughter, 2003). Slaughter's (2003) study also demonstrated that other physician 
actions included prescribing a different drug to almost 25% of patients, suggesting a 
lifestyle change in almost 40% of patients, and recommending an over the counter drug 
in more than 10% of patients. No action was taken in 18% of visits. Patients report that 
the most common reasons they did not receive the marketed product was because a 
different drug was believed to be more clinically appropriate, treatment was felt to be 
unnecessary or not indicated, or cost. 
Allison-Ottey's (2003) study reported that 36% of physicians said that patients 
came in for a visit solely because of advertisements, with 90% stating that patients have 
asked for their opinion because of ads. Fifty-three percent of physicians said that the ads 
promote patient education regarding disease states. This is more or less supported by the 
patient arm of the study. Of the patients assessed, 23% reported that they had a question 
for the physicians as a result of the advertisement and this quest for knowledge prompted 
most of them to look for more information to help them discuss the issue with their 
physician. Forty-eight percent of patients felt that the ads helped them make better 
decisions or helped them become better informed of the disease and treatments available. 
An interesting study showing better overall treatment of a population of patients 
was conducted The purpose of the review was to examine whether the relative 
proportion of appropriate use and misuse of lipid lowering therapies, also known as 
statins, changed between 1997 and 1999. During this time, there was an increase in the 
use of DTC advertising in general and in particular, an increase in marketing this class of 
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drugs. Results show that stalin use increased by 60% during this time period. Further 
analysis showed that almost 95% of patients on lipid lowering therapy had some 
documented objective level of cardiovascular risk, meaning either risk factors putting 
them at greater risk of a heart attack or stroke or a previous cardiovascular or 
cerebrovascular event. Therefore, the rising number of prescriptions came from 
appropriate prescribing of these products, suggesting an increased identification of 
patients needing this type of treatment (Dubois et a!., 2002). 
Another study, a quasi-experimental study examining the data from the 
MarketScan database for more than 30,000 patients between the years 1997 to 2000, 
suggests that DTCA had a beneficial effect on treatment of patients with depression. The 
investigators found that the number of patients diagnosed with depression and receiving 
appropriate treatment occurred in conjunction with an increase of DTC marketing of 
these products; in fact, patients had 32% higher relative odds of being put on therapy 
compared with times when DTC spending for marketing in the depression market was 
lowest. The investigators also assessed the effect of direct to physician marketing and 
found that marketing was not associated with either the initiation of treatment or with an 
appropriate duration of therapy with an antidepressant (Donohue, Berndt, Rosenthal, 
Epstein, & Frank, 2004). 
Does DTC enhance the healthcare professional to patient relationship? . 
Although other studies have suggested an increased tension between doctor and 
patient due to reliance on DTC marketing, there has been some evidence supporting the 
beneficial effects of these conversations between HCP and patient. In fact, much of this 
evidence comes from the same studies reporting that some physicians feel increasing 
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tension from these marketing informed discussions. A survey by Murray et a!. (2003) 
showed that 33% of physicians felt that discussion regarding DTC advertising improved 
the doctor-patient relationship; only 8% felt that it worsened it. Other studies showed 
that a large majority of patients reported that their doctor was very willing to talk to them 
about the advertised product and many felt that the interaction was positive (Slaughter, 
2003; Aiken 2003; Aiken, 2005). In fact, in one study, forty-three percent of patients 
surveyed felt the ads help them have better discussions with their doctor. One third of 
patients felt the DTC advertisements helped them formulate questions they wanted to ask 
their physician. The corresponding physician survey showed that 89% of physicians also 
perceived that DTCA was beneficial to their discussions with patients; many physicians 
stated that their patients asked better questions about their disease and that DTCA 
promoted communication between physicians and patients (Aiken, 2003; Aiken, 2004). 
Similar results were seen in other studies (Golodner, 2003; Allison-Ottey eta!., 2003). 
When asked about compliance, 30% of patients believe that advertisements 
remind people to take their medicines or refill their prescriptions. In fact, the majority of 
patients surveyed wanted to be more educated about the products and diseases and felt 
that information they obtained as a result of DTCA helped them prepare for an informed 
conversation with their physician (Allison-Ottey et a!., 2003). 
This is very important as DTC marketing sets physicians up as mediators between 
the patient and the pharmaceutical products. Welch-Cline and Young (2004) analyzed 
multiple print advertisements and concluded that since almost all of the assessed 
advertisements read "ask your doctor about drug X," this encourages the patient to 
initiate the interaction but established the physician as the general expert in this area, 
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approximately 75% of the advertisements. In only 15% of the analyzed advertisements 
are patients placed in controL 
Does DTC reduce stigmatization of certi.lin diseases? 
There is evidence, or at least a perception, that DTC marketing can help to de-
stigmatize certain diseases. Golodner (2003) reports that 42% of surveyed patients say 
that advertisements help de-stigmatize many conditions that may have gone untreated due 
to patient embarrassment and 46% say that advertisements help patients talk to their 
doctor about a condition that they believe they may have. Many patients are reluctant to 
talk to their physicians about potentially embarrassing diseases because they may feel 
that they are at fault for their disease state; in fact, medicalizing a condition and providing 
treatment for the disease may help patients overcome the embarrassment and seek 
treatment (Jones, 1998). Cutler and McClellan (2001) point out that "manufacturers of 
SSRis encouraged doctors to watch for depression, and the reduced stigma afforded by 
the new medications induced patients to seek help. As a result, diagnosis and treatment 
for depression doubled over the 1990s.". Incontinence is another disease that has become 
less stigmatized due to the marketing of certain drugs that treat it, such as Pfizer's Detro! 
(Gulfo, 2002). 
The stigmatization of diseases has been shown to lead to poorer quality of life for 
those suffering from them due to lack of interpersonal support as well as a reduction in 
health seeking behaviors, negatively affecting public health, especially for diseases that 
may lead to higher health expenditures for future emergency or chronic care of 
progressive disease with high morbidity. Additionally, this stigmatizing effect may lead 
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to reduced productivity of sufferers, which can have an economic effect due to lost wages 
and increased healthcare expenses for advanced disease treatment. Multiple groups have 
recommended broad methods to use to reduce stigmatization; these recommendations 
include public education and mass media campaigns using print, radio, and television, 
which are partly fulfilled by DTC marketing practices (DesJarlais, Galea, Tracy, Tross & 
Vlahov, 2006; Klein, Karchner, & O'Donnell, 2002). 
Harnessing the Power of DTC Marketing to Improve Pnblic Health. 
What has been obvious through this review of the evidence both for and against 
DTC marketing is that this is a controversial issue with no solid evidence definitively 
showing immense good or harm coming from this practice. In fact, in most of the studies 
presented in this paper, there was no general consensus about whether DTC marketing is 
inherently good or bad; most surveys showed that the participants acknowledged both 
beneficial and negative effects of DTC marketing as it is used today. 
Interestingly, recent developments in the healthcare industry, such as worries 
about long term safety issues due to the COX-2 scandal, has changed the face of DTCA. 
Merck was believed to cover up potential evidence that showed that use of the non-
steroidal anti-inflammatory drug Vioxx was related to an increased risk of cardiovascular 
events. Because of this, there has been a shift to more controlled marketing strategies by 
pharmaceutical companies, both at the behest of the FDA and on the part of the 
pharmaceutical companies themselves (Spence, Teleki, Cheetham, Schweitzer, & 
Millares, 2005; Young, 2005). The Pharmaceutical Research and Manufacturers of 
America (PhRMA) released a set of guidelines suggesting the advertisements be more 
focused on fair, balanced marketing that is meant to educate patients on a disease state 
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and any potential non pharmaceutical changes beyond pharmacological treatment. In 
addition, the advertisements should focus on fostering communication between HCPs and 
patients, with the pharmaceutical companies also spending more time educating the HCPs 
about questions the patients may have about their product prior to the release of DTC 
advertisements. The PhRMA guidelines also suggest that pharmaceutical companies 
submit any DTC television advertisements for FDA review before releasing the 
advertisements for broadcast (PhRMA, 2005). 
Twenty seven pharmaceutical companies, such as Pfizer and Lilly, have adopted 
these guidelines ("Congress Likely To Debate Moratoriums On Direct-To-Consumer 
Prescription Drug Advertisement," 2007). Pfizer and Johnson & Johnson, for instance, 
have instituted a 6 month moratorium on DTC advertisements for new medications, 
agreeing not to market newly approved products to patients for a minimum of 6 months. 
They have also stated that they will improve the presentation of safety information for all 
their products ("Pfizer Announces It Will Limit DTC Ads To Medications That Have 
Been On Market For At Least Six Months," 2005; Freudenheim, 2007). Bristol-Myers 
Squibb has initiated a one year moratorium. Additionally, the companies have made a 
concerted effort to better target their audiences; for instance, Lilly is restricting the 
marketing efforts for a Cialis, a drug for treatment of erectile dysfunction, to those times 
when they believe that at least 80% of the audience attracted will be an adults (HJKF, 
2006). The FDA is looking to enact a regulation that will have the pharmaceutical 
companies pay a fee to increase and quicken review of all DTC television broadcast ads. 
These payments will go towards increasing manpower at the FDA ("FDA Proposes 29% 
Increase in User Fees Paid By Pharmaceutical Companies," 2007). 
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As the recent survey by Price Waterhouse Coopers (2007) shows, the public's 
trust in the pharmaceutical industry has eroded significantly due, in large part, to 
misconceptions about the goals of the industry. Of course, this industry, like all 
industries, is interested in turning a profit. This profit, however, is crucial to the future of 
the healthcare system in the United States. Most of the innovative pharmaceutical 
treatments for the world are first available in the United States. However, for each 
treatment that is approved for use in patients, a multitude fails. 
On average, economists estimate that it takes 10-15 years to develop a new drug. 
Additionally, they note that only about one out of five drugs that enter into human 
clinical trials is approved by the FDA. This does not include those that fail in preclinical 
studies and do not make it to clinical trials. Some economists estimate that only 20 in 
5000 compounds make it into preclinical studies. This inevitably leads to very high drug 
development costs (Glover, 2002). Market dynamics then lead pharmaceutical 
companies to rely heavily on marketing practices, both to physicians and patients, with 
successful marketing allowing for additional investment in research and development 
(Calfee, 2000; Calfee, 2002). Increasing the pharmaceutical companies ability to 
continue to develop innovative new products to treat some of the world's most 
challenging and pervasive chronic and acute diseases is crucial for the public's health. 
Moreover, increased funding could allow pharmaceutical companies to also concentrate 
on diseases that may not be as widespread but cause significant morbidity or mortality to 
those affected. 
Proponents note that the biggest benefit for DTC marketing is in its ability to 
promote disease awareness and, if the industry was more focused on unbranded disease 
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awareness marketing initiatives, DTC marketing would be looked upon more favorably 
by all stakeholders such as patients, federal officials, and HCPs (NMA, 2002; Welch-
Cline & Young, 2004; Bodenheimer, 2003; PhRMA, 2005; Aiken, 2005). Therefore, 
partnerships between industry and the medical field to promote disease awareness 
through DTC of diseases that are not well understood, under-diagnosed, or stigmatized 
might be beneficial in promoting public health. 
This is not to say tbat some movement towards increased disease awareness 
advertising has not occurred. Recent data examining awareness of DTC advertising from 
1998 to 2005 showed that since 2001, awareness of disease awareness ads has increased 
7%, suggesting a greater investment in that form of marketing could be beneficial if 
pharmaceutical companies focused more resources on that realm in order to increase 
overall disease awareness (Aiken, 2005). 
Though DTC marketing of specific pharmaceutical products can not be 
completely eliminated, and arguably, should not be, the partnership of industry and the 
medical field could promote higher opinions of the field in general. Additionally, a 
closer relationship between medical associations and the FDA could potentially promote 
better presentation of medical data even in branded pieces--data that would be clinically 
and medically relevant to the patients in question and would contain less "spin" to 
confuse them about the potential benefits and risks of the products. More focus on non-
pharmacological treatments, such as lifestyle changes, would also be an important 
component of these marketing initiatives. 
Another important consideration for the future of DTCA is that diversity has not 
been well promoted in DTC marketing efforts. An analysis of different DTC print ads 
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showed predominately Caucasian models, with few African American (AA) or Hispanic 
models. In fact, those advertisements that used AA or Hispanic models were very 
specific to diseases like HIV. Therefore, the authors conclude that "beyond promoting 
social stereotypes lies the potential for [DTC's] visual cues to reinforce already existing 
disparities in access to health information and, to the extent that ads promote visits to 
physicians, disparities in access to health care. To the extent that DTC has the 
educational potential that proponents have argued, DTC may widen the gap between the 
haves and have-nots" (Welch Cline & Young, 2004). 
However, there is an opportunity for the pharmaceutical industry to better 
promote health for a multiracial population. Dr. Allison-Ottey, who was a leading figure 
for the National Medical Association (NMA), an organization for AA healthcare 
professionals, encourages the use of DTC marketing to increase disease awareness in the 
AA population, as long as the marketing is fair and provides an adequate fair balance 
assessment. (Allison-Ottey, 2002). Additionally, in the official position of the NMA to 
DTC marketing, the NMA (2002) suggests that they and the pharmaceutical industry 
partner so that the input of AA physicians and patients are included. The position 
statement concludes with the statement, "Physicians must be open to alternative methods 
of communicating health information such as DTC advertisements as long as the 
information is balanced and outlines the risks versus benefits of any products." 
The public health implications for effective DTCA are potentially great. 
Empowering patients by providing important information that could prepare them to ask 
the correct questions or feel more comfortable speaking with their physicians could 
increase health seeking behaviors and help them obtain treatment earlier and optimally 
28 
Master's Paper Final 
4/2/2007 
Serena Tsai 
move them towards preventative practices to minimize their risk of future diseases. A 
more medically informed population of Americans could lead to a healthier population 
and reduce excess spending on emergency and chronic care. Proper health care and 
healthy behaviors could also reduce additional disease associated morbidities, that could 
have been avoided had patients been effectively managed from the beginning. 
An example of this is Merck's recent "Tell Someone" and "Make the Connection" 
campaigns supporting HPV disease education separately from promoting the vaccine. 
These multi-lingual disease awareness programs educate about the link between cervical 
cancer and HPV, encouraging regular screening and preventative care and providing 
support to national and local organizations to reach a broad, diverse target audience. The 
efficacy of this campaign is, in part, demonstrated by the media attention given to the 
importance of these vaccines and the political noise surrounding states that are debating 
making this vaccine mandatory for school aged girls ("Merck Launches National 
Advertising Campaign for GARDASIL®, Merck's New Cervical Cancer Vaccine," 
2006). 
Conclusion: 
A multitude of surveys and studies have shown that the role of pharmaceutical 
marketing, especially DTC marketing of specific products, plays in promotion of 
healthful practices is not well elucidated. Future studies should be done to continue to 
understand the impact of this marketing practice on furthering the public's health. It is 
also important to be able to define what the effect of the demonstrated health seeking 
behavior has on public health outcomes, such as a reduction in overall costs to the 
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healthcare system, fewer emergency visits related to lack of optimal treatments, or 
reduction in morbidities associated with chronic or preventable diseases. 
Current studies show that disease awareness campaigns, such as Merck's "Tell 
Someone" is perceived as the best way to promote health benefits. Patient and physician 
associations seem to be especially likely to support these campaigns. Getting multiple 
stakeholders to support these marketing efforts by using more disease awareness 
campaigns could positively impact public health, but also, improve public perception of 
the pharmaceutical industry. Partnerships between stakeholders such as policy makers, 
public health associations, the medical field, and the pharmaceutical industry may be 
synergistic in benefiting the public's health. At this point, our public health system needs 
as much help as it can get. 
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